Isoray Announces Third Quarter Fiscal 2021 Financial Results

Revenue Increased 10% Sequentially Record Non-Prostate Brachytherapy Revenue Increased 20% Year-Over-Year   RICHLAND, WASHINGTON – May 13, 2021 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering...

Isoray Announces Second Quarter Fiscal 2021 Financial Results

Revenue Increased 7% Year-Over-Year Non-Prostate Brachytherapy Revenue Increased 92% Year-Over-Year   RICHLAND, WASHINGTON – February 9, 2021 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding...

Isoray Announces Pricing of $45 Million Public Offering

RICHLAND, Wash., February 4, 2021 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, announced the pricing of its public offering of 36,000,000 shares of...

Isoray Announces Proposed Underwritten Public Offering

RICHLAND, Wash., February 3, 2021 – Isoray, Inc. (NYSE AMERICAN: ISR) (“Isoray” or the “Company”), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced that it intends to offer...